Cost-effectiveness analysis of pneumococcal conjugate vaccines in preventing pneumonia in Peruvian children
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Autor
Mezones-Holguín, EdwardBolaños Díaz, Rafael
Fiestas, Víctor
Sanabria, César
Gutiérrez Aguado, Alfonso
Fiestas, Fabián
Suárez, Víctor J.
Rodríguez Morales, Alfonso J.
Hernández, Adrian V.
Fecha de publicación
2015-01-08Palabras clave
PneumococcalPneumococcal vaccines
Cost-effectiveness
Immunization programs
Peru
Pneumonia
Metadatos
Mostrar el registro completo del ítemCitation
Mezones-Holguín E, Bolaños-Díaz R, Fiestas V, Sanabria C, Gutiérrez-Aguado A, Fiestas F, et al. Cost-effectiveness analysis of pneumococcal conjugate vaccines in preventing pneumonia in Peruvian children. The Journal of Infection in Developing Countries [Internet]. 15 de diciembre de 2014 [citado 8 de enero de 2015];8(12). Recuperado a partir de: http://www.jidc.org/index.php/journal/article/view/25500653Journal
The Journal of Infection in Developing Countries (J Infect Dev Ctries)Enlaces adicionales
http://www.jidc.org/index.php/journal/article/view/25500653Resumen
Introduction: Pneumococcal pneumonia (PP) has a high burden of morbimortality in children. Use of pneumococcal conjugate vaccines (PCVs) is an effective preventive measure. After PCV 7-valent (PCV7) withdrawal, PCV 10-valent (PCV10) and PCV 13-valent (PCV13) are the alternatives in Peru. This study aimed to evaluate cost effectiveness of these vaccines in preventing PP in Peruvian children <5 yearsold. Methodology: A cost-effectiveness analysis was developed in three phases: a systematic evidence search for calculating effectiveness; a cost analysis for vaccine strategies and outcome management; and an economic model based on decision tree analysis, including deterministic and probabilistic sensitivity analysis using acceptability curves, tornado diagram, and Monte Carlo simulation. A hypothetic 100 vaccinated children/vaccine cohort was built. An incremental cost-effectiveness ratio (ICER) was calculated. Results: The isolation probability for all serotypes in each vaccine was estimated: 38% for PCV7, 41% PCV10, and 17% PCV13. Avoided hospitalization was found to be the best effectiveness model measure. Estimated costs for PCV7, PCV10, and PCV13 cohorts were USD13,761, 11,895, and 12,499, respectively. Costs per avoided hospitalization were USD718 for PCV7, USD333 for PCV10, andUSD 162 for PCV13. At ICER, PCV7 was dominated by the other PCVs. Eliminating PCV7, PCV13 was more cost effective than PCV10 (confirmed in sensitivity analysis). Conclusions: PCV10 and PCV13 are more cost effective than PCV7 in prevention of pneumonia in children <5 years-old in Peru. PCV13 prevents more hospitalizations and is more cost-effective than PCV10. These results should be considered when making decisions about the Peruvian National Inmunizations Schedule.Tipo
info:eu-repo/semantics/articleDerechos
info:eu-repo/semantics/openAccessIdioma
engDescripción
[email protected]ISSN
2036-6590EISSN
1972-2680Colecciones
El ítem tiene asociados los siguientes ficheros de licencia: